OXFORD, UK - British techbio innovator Etcembly is set to launch a groundbreaking new research study aimed at uncovering new targets for cancer therapeutics by analysing the immune cells of cancer survivors.
The ETCh study is rooted in the well-established concept that long-term survivors have beaten cancer due to their immune system’s ability to recognise and eliminate cancerous cells. However, a systematic search for the specific targets recognised within tumours has yet to be undertaken.
In this study, blood samples will be collected from people who are living with or have survived cancer as well as healthy individuals. The research team will conduct an extensive analysis of the immune repertoire at an unprecedented scale by sequencing millions of antibodies and T cell receptors (TCRs) from each participant.
Etcembly’s advanced AI platform, EMLy™, will then perform an in-depth analysis to identify which of these are likely to play a role in recognising and destroying cancer cells, and determine the aberrant molecules in tumours that they target.
These molecules could become new targets for next-generation immunotherapies that harness the power of a patient’s own immune system to combat cancer. The team expects to identify new targets within 12 to 18 months, which will then enter Etcembly’s pipeline for developing novel TCR-based therapies.
The ETCh study is due to launch in August 2024. Follow Etcembly on LinkedIn to stay up to date with the latest news.To find out more or in us in our journey to discover new treatments for a cancer free future, go to Etcembly's Long Term Survivor Study
Comments